Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2016-02-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 255
- Registration Number
- NCT02598063
Observational Study of Methoxy Polyethylene Glycol Epoetin Beta Daily Use in Participants on Peritoneal Dialysis
- Conditions
- Renal ImpairmentRenal Anemia of Chronic Kidney Disease
- Interventions
- Drug: Methoxy polyethylene glycol epoetin beta
- First Posted Date
- 2015-11-04
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 223
- Registration Number
- NCT02596945
- Locations
- 🇩🇪
Dres. Michael Koch Hannelore Klimke Wolfgang Kulas u.w., Mettmann, Germany
A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)
- Conditions
- Diffuse Large B-Cell Lymphoma, Lymphoma Follicular
- Interventions
- First Posted Date
- 2015-11-04
- Last Posted Date
- 2021-05-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 91
- Registration Number
- NCT02596971
- Locations
- 🇦🇺
Concord Repatriation General Hospital; Haematology, Sydney, New South Wales, Australia
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Oncology Associates of Oregon, P.C.; Willamette Valley Cancer Institute, Springfield, Oregon, United States
Safety and Efficacy Study of Avastin in Locally Advanced Metastatic or Recurrent Non-small Lung Cancer (NSLC) Participants
- First Posted Date
- 2015-11-04
- Last Posted Date
- 2016-04-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 996
- Registration Number
- NCT02596958
A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
- Conditions
- Locally Advanced Breast CancerMetastatic Breast Cancer
- First Posted Date
- 2015-11-03
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 110
- Registration Number
- NCT02595762
- Locations
- 🇬🇷
ARETAIEION UNIVERSITY HOSPITAL; oncology unit, Athens, Greece
🇬🇷Agioi Anargyroi; 3Rd Dept. of Medical Oncology, Athens, Greece
🇬🇷Attikon University Hospital; 4th Department of Internal Medicine, Haidari, Greece
A Non-interventional Trial of Erlotinib (Tarceva) Metastatic Non-small Cell Lung Cancer
- First Posted Date
- 2015-11-03
- Last Posted Date
- 2016-01-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 299
- Registration Number
- NCT02595450
A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)
- First Posted Date
- 2015-11-01
- Last Posted Date
- 2018-05-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 10
- Registration Number
- NCT02593760
- Locations
- 🇺🇸
Florida Cancer Specialists, West Palm Beach, Florida, United States
🇺🇸Oncology Hematology Care Inc, Cincinnati, Ohio, United States
🇺🇸Florida Cancer Specialists-Broadway, Fort Myers, Fort Myers, Florida, United States
An Observational Study to Describe in Routine Clinical Practice the Treatment Patterns of Usage of Biological DMARDs in RA Patients.
- Conditions
- Rheumatoid Arthritis
- Interventions
- Other: Routine clinical practice
- First Posted Date
- 2015-10-29
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 808
- Registration Number
- NCT02590562
- Locations
- 🇨🇳
China-Janpan Friendship Hospital of Jilin University, Changchun, China
🇨🇳Beijing Jishutan Hospital; Rheumatology & Immunology, Beijing, China
🇨🇳Peking University Third Hospital, Beijing, China
A Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal Disease Awaiting Transplantation
- Conditions
- Kidney Failure, Chronic
- Interventions
- Drug: ObinutuzumabDrug: Intravenous Immunoglobulin
- First Posted Date
- 2015-10-26
- Last Posted Date
- 2020-01-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT02586051
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸UCSF, San Francisco, California, United States
🇺🇸Mayo Clinic - Minnesota, Rochester, Minnesota, United States
Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel
- Conditions
- Breast Cancer
- Interventions
- Drug: FEC ChemotherapyProcedure: SurgeryDrug: DocetaxelDrug: PlaceboDrug: PertuzumabDrug: Trastuzumab
- First Posted Date
- 2015-10-26
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 329
- Registration Number
- NCT02586025
- Locations
- 🇨🇳
Taipei Medical University ?Shuang Ho Hospital, New Taipei City, Taiwan
🇨🇳China Medical University Hospital; Surgery, Taichung, Taiwan
🇹🇭Bhumibol Adulyadej Hospital; Medicine, Bangkok, Thailand